DaVita Inc. $DVA Stock Holdings Raised by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S lifted its stake in shares of DaVita Inc. (NYSE:DVA) by 41.6% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 121,751 shares of the company’s stock after purchasing an additional 35,751 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in DaVita were worth $18,712,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Elevation Wealth Partners LLC raised its stake in DaVita by 147.3% during the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after buying an additional 165 shares in the last quarter. Caitlin John LLC bought a new stake in shares of DaVita in the 4th quarter valued at approximately $34,000. Canada Pension Plan Investment Board bought a new stake in shares of DaVita in the 2nd quarter valued at approximately $43,000. Sankala Group LLC acquired a new stake in shares of DaVita during the 4th quarter valued at approximately $39,000. Finally, iSAM Funds UK Ltd bought a new position in DaVita during the third quarter worth $46,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. TD Cowen increased their target price on shares of DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a report on Monday, May 11th. Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Truist Financial raised their target price on shares of DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a report on Friday, May 8th. Finally, Barclays lifted their target price on DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $199.17.

DaVita Stock Performance

DaVita stock opened at $207.65 on Friday. DaVita Inc. has a one year low of $101.00 and a one year high of $213.44. The company has a 50-day simple moving average of $182.22 and a 200-day simple moving average of $149.19. The firm has a market capitalization of $13.33 billion, a P/E ratio of 19.26, a P/E/G ratio of 0.68 and a beta of 0.91.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.54. The firm had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. DaVita’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same period last year, the firm posted $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, sell-side analysts forecast that DaVita Inc. will post 15.07 earnings per share for the current year.

Insider Activity at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of DaVita stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the sale, the insider owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares of the company’s stock, valued at approximately $25,440,571.40. This represents a 27.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.50% of the stock is currently owned by company insiders.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.